Functional Consequences of Mutations in Amino Acid Residues that Stabilize Calcium Binding to the First Epidermal Growth Factor Homology Domain of Human Protein C

Summary Charge-to-alanine mutations of three amino acid residues, viz., D46, D48, and D/Hya71, which are known to be important in stabilizing Ca2+ binding to epidermal growth factor (EGF) domains of vitamin K-de-pendent blood coagulation proteins, have been engineered into recombinant human protein C (r-PC), The resulting variants were then employed to assess the importance of this Ca2+ binding site in the activation properties of r-PC and in the activity of activated protein C (APC). Another mutation, of D48 to E, was constructed in order that a more conservative mutation at the Ca2+ binding site could be similarly examined. The mutant proteins were fully processed with regard to proper signal peptide cleavage, γ-carboxylation, and β-hydroxylation, except, of course, for the D71A mutant in this latter case. The D48E variant possessed an additional residue of γ-carboxyglutamic acid (Gla), showing that E48 was γ-carboxylated. All of the mutants were reactive against a monoclonal antibody (MAb) specific for a Ca2+-dependent epitope within the amino-terminus of the Gla domain of r-PC, demonstrating that a proper Ca2+-dependent conformation was adopted in this region of the protein. None of the mutants, except for [D48γ]r-PC, were reactive against another Ca2+-dependent MAb which possessed specificity for Ca2+ binding to the EGF1 region of PC-this being the area of the protein that contained the mutated residues. These data strongly suggest that the alanine mutations present at D46, D48, and D71 diminished Ca2+ binding to the EGF1 domain of r-PC. Steady state kinetic analysis demonstrated that determinants for the Ca2+-dependent inhibition of the thrombin (flla)-catalyzed activation of r-PC, and for the kinetic recognition of the flla/thrombomodulin complex, were not dependent on the integrity of the Ca2+ sites present in EGF1. The lone exception was [D48γ]r-PC, which did not undergo inhibition by Ca2+, an effect likely due to the potential for altered coordination of Ca2+ due to the Gla insertion, rather than to a dependency on D48. Plasma-based anticoagulant assays, as well as individual factor Va and factor Villa inactivation assays, showed that only [D71A]r-APC possessed a significantly reduced activity compared to wild-type r-APC. These observations suggest that D/Hya71 is likely an important determinant for activity of APC toward its physiological substrates, factor Va and factor Villa.

[1]  P. Handford,et al.  The structure of a Ca2+-binding epidermal growth factor-like domain: Its role in protein-protein interactions , 1995, Cell.

[2]  J. Birktoft,et al.  High Affinity Ca2+-binding Site in the Serine Protease Domain of Human Factor VIIa and Its Role in Tissue Factor Binding and Development of Catalytic Activity (*) , 1995, The Journal of Biological Chemistry.

[3]  F. Castellino,et al.  Calcium and phospholipid binding properties of synthetic gamma-carboxyglutamic acid-containing peptides with sequence counterparts in human protein C. , 1994, Biochemistry.

[4]  F. Castellino,et al.  The activities of recombinant gamma-carboxyglutamic-acid-deficient mutants of activated human protein C toward human coagulation factor Va and factor VIII in purified systems and in plasma. , 1994, Biochemistry.

[5]  F. Sussman,et al.  Mutation of Glu-80-->Lys results in a protein C mutant that no longer requires Ca2+ for rapid activation by the thrombin-thrombomodulin complex. , 1994, The Journal of biological chemistry.

[6]  F. Castellino,et al.  Construction, expression, and properties of a recombinant chimeric human protein C with replacement of its growth factor-like domains by those of human coagulation factor IX. , 1994, Biochemistry.

[7]  I. Campbell,et al.  The effect of aspartate hydroxylation on calcium binding to epidermal growth factor-like modules in coagulation factors IX and X. , 1993, The Journal of biological chemistry.

[8]  C. Esmon,et al.  Analysis of the functions of the first epidermal growth factor-like domain of factor X. , 1993, The Journal of biological chemistry.

[9]  E. Blasko,et al.  The short loop between epidermal growth factor-like domains 4 and 5 is critical for human thrombomodulin function. , 1993, The Journal of biological chemistry.

[10]  F. Castellino,et al.  Binding of calcium to synthetic peptides containing gamma-carboxyglutamic acid. , 1993, International journal of peptide and protein research.

[11]  M. Ullner,et al.  How an epidermal growth factor (EGF)-like domain binds calcium. High resolution NMR structure of the calcium form of the NH2-terminal EGF-like domain in coagulation factor X. , 1994, The Journal of biological chemistry.

[12]  C. Esmon,et al.  The function of calcium in protein C activation by thrombin and the thrombin-thrombomodulin complex can be distinguished by mutational analysis of protein C derivatives. , 1992, The Journal of biological chemistry.

[13]  J. Lin,et al.  Oxidation of a specific methionine in thrombomodulin by activated neutrophil products blocks cofactor activity. A potential rapid mechanism for modulation of coagulation. , 1992, The Journal of clinical investigation.

[14]  I. Campbell,et al.  Ligand requirements for Ca2+ binding to EGF-like domains. , 1992, Protein engineering.

[15]  F. Castellino,et al.  Role of individual gamma-carboxyglutamic acid residues of activated human protein C in defining its in vitro anticoagulant activity. , 1992, Blood.

[16]  C. Esmon,et al.  The high affinity calcium-binding site involved in protein C activation is outside the first epidermal growth factor homology domain. , 1992, The Journal of biological chemistry.

[17]  F. Castellino,et al.  Role of tryptophan-74 of the recombinant kringle 2 domain of tissue-type plasminogen activator in its omega-amino acid binding properties. , 1992, Biochemistry.

[18]  F. Castellino,et al.  Expression, purification, and characterization of the recombinant kringle 1 domain from tissue-type plasminogen activator. , 1992, Archives of biochemistry and biophysics.

[19]  S. Bajaj,et al.  Antibody-probed conformational transitions in the protease domain of human factor IX upon calcium binding and zymogen activation: putative high-affinity Ca(2+)-binding site in the protease domain. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[20]  F. Castellino,et al.  Role of the hexapeptide disulfide loop present in the gamma-carboxyglutamic acid domain of human protein C in its activation properties and in the in vitro anticoagulant activity of activated protein C. , 1991, Biochemistry.

[21]  J. Walls,et al.  Glycosylation of human protein C affects its secretion, processing, functional activities, and activation by thrombin. , 1991, The Journal of biological chemistry.

[22]  I. D. Campbell,et al.  Key residues involved in calcium-binding motifs in EGF-like domains , 1991, Nature.

[23]  P. Winship,et al.  Identification of haemophilia B patients with mutations in the two calcium binding domains of factor IX: importance of a β‐OH Asp 64→Asn change , 1991, British journal of haematology.

[24]  D. Monroe,et al.  Characterization of the functional defect in factor IX Alabama. Evidence for a conformational change due to high affinity calcium binding in the first epidermal growth factor domain. , 1990, The Journal of biological chemistry.

[25]  I. Campbell,et al.  The first EGF‐like domain from human factor IX contains a high‐affinity calcium binding site. , 1990, The EMBO journal.

[26]  D. Bentley,et al.  Molecular pathology of haemophilia B. , 1989, The EMBO journal.

[27]  B. Lämmle,et al.  Immunoblotting studies of the molecular forms of protein C in plasma. , 1988, Thrombosis research.

[28]  S. Linse,et al.  Calcium binding to the epidermal growth factor homology region of bovine protein C. , 1988, The Journal of biological chemistry.

[29]  S. Yamamoto,et al.  Structure and expression of human thrombomodulin, a thrombin receptor on endothelium acting as a cofactor for protein C activation. , 1987, The EMBO journal.

[30]  J. Ware,et al.  Factor IXAlabama: a point mutation in a clotting protein results in hemophilia B. , 1987, Blood.

[31]  Y. Sakata,et al.  Conformation-specific monoclonal antibodies to the calcium-induced structure of protein C. , 1986, The Journal of biological chemistry.

[32]  Thomas A. Kunkel,et al.  Rapid and efficient site-specific mutagenesis without phenotypic selection. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[33]  C. Esmon,et al.  Proteolytic formation and properties of gamma-carboxyglutamic acid-domainless protein C. , 1983, The Journal of biological chemistry.

[34]  C. Esmon,et al.  Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C. , 1982, The Journal of biological chemistry.

[35]  W. Kisiel,et al.  Interaction of calcium with bovine plasma protein C. , 1981, Biochemistry.

[36]  E. Davie,et al.  Preparation and properties of bovine factor VIII (antihemophilic factor). , 1980, Biochemistry.

[37]  W. Kisiel,et al.  Anticoagulant properties of bovine plasma protein C following activation by thrombin. , 1977, Biochemistry.

[38]  G. Nelsestuen Role of gamma-carboxyglutamic acid. An unusual protein transition required for the calcium-dependent binding of prothrombin to phospholipid. , 1976, The Journal of biological chemistry.